TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29505528

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (RHE)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.9% saline (Control)
Number of subjects: 120
Study: 26811525

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily plus trametinib 2 mg daily (150/2 group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 78
Study: 25048383

Group type: EXPERIMENTAL
Intervention: Albiglutide (once-weekly subcutaneous)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sitagliptin (daily)
Number of subjects: 0
Study: 22741450

Group type: EXPERIMENTAL
Intervention: Tadalafil + testosterone undecanoate
Number of subjects: 125

Group type: COMPARATOR
Intervention: Testosterone undecanoate alone
Number of subjects: 125
Study: 20231531

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17898654

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) 50 mg/m
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional daunorubicin 50 mg/m
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Conventional daunorubicin
Number of subjects: 14
Study: 16328128

Group type: EXPERIMENTAL
Intervention: Delayed primary closure (Group 1, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Primary closure (Group 2, n = 20)
Number of subjects: 40
Study: 12488411

Group type: EXPERIMENTAL
Intervention: Chemotherapy with etoposide and cisplatin (EP)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Chemotherapy with cyclophosphamide, epirubicin, and vincristine (CEV)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: EP in limited disease (LD) patients
Number of subjects: 436

Group type: COMPARATOR
Intervention: CEV in limited disease (LD) patients
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: EP in extensive disease (ED) patients
Number of subjects: 436

Group type: COMPARATOR
Intervention: CEV in extensive disease (ED) patients
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Quality-of-life assessments
Number of subjects: 436
Study: 9816714

Group type: EXPERIMENTAL
Intervention: PCA nalbuphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 60
Study: 7654161

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Electromyographic Biofeedback (EMGBF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wait List Control (WLC)
Number of subjects: 44
Study: 2653757

Group type: EXPERIMENTAL
Intervention: Two different diabetes treatment regimens
Number of subjects: 0
Study: 787050

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline 0.25 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous terbutaline 0.5 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31646723

Group type: EXPERIMENTAL
Intervention: Fast-track ambulatory abscess pathway (FAAP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pre-ambulatory care pathway
Number of subjects: 100
Study: 30629126

Group type: EXPERIMENTAL
Intervention: Higher protein weight loss program (1.2-1.5 g/kg/d)
Number of subjects: 96
Study: 28921537

Group type: EXPERIMENTAL
Intervention: Bougie technique
Number of subjects: 257
Study: 26983578

Group type: EXPERIMENTAL
Intervention: Veterans' In‐home Programme (VIP)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual-care enhanced by two attention‐control telephone calls (Control)
Number of subjects: 81
Study: 25160516

Group type: EXPERIMENTAL
Intervention: Child Support Grant (CSG) application
Number of subjects: 3494
Study: 21960110

Group type: EXPERIMENTAL
Intervention: Doxorubicin/cyclophosphamide (AC) followed by docetaxel (Doc)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Doxorubicin/pemetrexed (AP) followed by docetaxel (Doc)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Hormone receptor-positive subgroup
Number of subjects: 257

Group type: COMPARATOR
Intervention: CD24 3'UTR (TG/Del) genotype
Number of subjects: 257
Study: 19642984

Group type: EXPERIMENTAL
Intervention: Diabetes Needs Assessment Tool (DNAT) plus diabetes learning modules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diabetes learning modules alone (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (DNAT and control)
Number of subjects: 0
Study: 17132650

Group type: EXPERIMENTAL
Intervention: Adenosine (50 microg bolus before wiring of each lesion)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard treatment (no adenosine pretreatment)
Number of subjects: 62
Study: 15918933

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty with or without stent placement (CAS)
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 1154
Study: 12669445

Group type: EXPERIMENTAL
Intervention: Modified Sclerotherapy (5% Sodium Morrhate + Triamcinolone Acetonide)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Traditional Sclerotherapy (5% Sodium Morrhate)
Number of subjects: 138
Study: 10022415

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment, acute (4-5 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment, short-term (5 days)
Number of subjects: 0
Study: 7767194

Group type: EXPERIMENTAL
Intervention: Hyperbaric chamber treatment at 193 mbar for 1 hour
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dexamethasone (8 mg initially, followed by 4 mg after 6 hours)
Number of subjects: 31
Study: 2312782

Group type: EXPERIMENTAL
Intervention: Quinidine sulfate 200 mg orally every 8 hours for 24 hours prior to antipyrine administration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Antipyrine 1 gram dose alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quinidine sulfate
Number of subjects: 6
Study: 6774845

Group type: EXPERIMENTAL
Intervention: 5700 rad in 19 treatments, 24 days overall
Number of subjects: 74

Group type: COMPARATOR
Intervention: 4580 rad in 10 treatments, 11 days overall
Number of subjects: 74
Study: 31628783

Group type: EXPERIMENTAL
Intervention: ABP 710 (5 mg/kg intravenously over 2 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Infliximab US (5 mg/kg intravenously over 2 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Infliximab EU (5 mg/kg intravenously over 2 hours)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ABP 710
Number of subjects: 150

Group type: COMPARATOR
Intervention: Infliximab US
Number of subjects: 150

Group type: COMPARATOR
Intervention: Infliximab EU
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ABP 710, infliximab US, infliximab EU
Number of subjects: 150
Study: 31277259

Group type: EXPERIMENTAL
Intervention: Guava fruit extract prepared by supercritical CO2 extraction
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (glucose solution)
Number of subjects: 31
Study: 29390538

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy (35 to 45 minutes, 2 times/week for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional drug therapy only
Number of subjects: 90
Study: 26282635

Group type: EXPERIMENTAL
Intervention: FOLFOX (fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 346
Study: 23895758

Group type: EXPERIMENTAL
Intervention: Hook plate fixation
Number of subjects: 105

Group type: COMPARATOR
Intervention: Suture-anchor fixation
Number of subjects: 105
Study: 21978192

Group type: EXPERIMENTAL
Intervention: acuPRP (manual acupuncture before PRP treatment)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no acupuncture before PRP treatment)
Number of subjects: 34
Study: 19210162

Group type: EXPERIMENTAL
Intervention: NNRTI strategy with NNRTI-resistance mutation detected by ultra-deep sequencing
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: NNRTI strategy with NNRTI-resistance mutation detected by standard and ultra-deep sequencing
Number of subjects: 1397

Group type: EXPERIMENTAL
Intervention: NNRTI strategy with mutation(s) detected only with ultra-deep sequencing
Number of subjects: 1397

Group type: COMPARATOR
Intervention: NNRTI strategy without NNRTI-resistance mutations
Number of subjects: 1397
Study: 17074704

Group type: EXPERIMENTAL
Intervention: Cooperative assessment structure in problem-based learning (PBL) tutorials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual, lecture-based learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooperative assessment structure in PBL
Number of subjects: 0
Study: 15501951

Group type: EXPERIMENTAL
Intervention: Targeted clinical trial design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untargeted clinical trial design
Number of subjects: 0
Study: 10342783

Group type: EXPERIMENTAL
Intervention: Low-sodium mineral salt (19% reduction in urinary sodium)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (12% increase in urinary sodium)
Number of subjects: 86
Study: 8949759

Group type: EXPERIMENTAL
Intervention: Conformal neutron/photon irradiation (15 NGy + 18 PhGy)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conformal photon irradiation (25 patients/78 Gy and 24 patients/83 Gy minimum dose)
Number of subjects: 96
Study: 1997131

Group type: EXPERIMENTAL
Intervention: 55 micrograms Se/d as Se-rich meat or bread
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 135 micrograms Se/d as Se-rich meat or bread
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 215 micrograms Se/d as Se-rich meat or bread
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (unsupplemented subjects)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-Se meat
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All Se intake levels
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 24
Study: 6119443

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole alone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Co-trimoxazole with framycetin and colistin
Number of subjects: 43
Study: 31358685

Group type: EXPERIMENTAL
Intervention: Productive Ward: Releasing Time to Care programme
Number of subjects: 0
Study: 31104760

Group type: EXPERIMENTAL
Intervention: Group A (received description of diagnostic criteria)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Group B (no description of diagnostic criteria)
Number of subjects: 126
Study: 27278921

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM) 1000-1500 mg iron
Number of subjects: 252

Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FS) 200 mg iron/day
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Oral ferrous sulfate (FS)
Number of subjects: 252
Study: 25451910

Group type: EXPERIMENTAL
Intervention: Pragmatic diabetes risk reduction intervention
Number of subjects: 59
Study: 22352931

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg diazepam and 10 mg/kg ketamine (Parnell Laboratories NZ Ltd)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5 mg/kg diazepam and 10 mg/kg ketamine (Ketalar; Hospira NZ Ltd)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 μg/kg medetomidine and 2 mg/kg alphaxalone
Number of subjects: 30
Study: 20496741

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 19

Group type: COMPARATOR
Intervention: Acupuncture combined with bloodletting therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine (e.g., catgut embedding therapy with Fluoxetine, electroacupuncture with Seroxat)
Number of subjects: 19
Study: 17688075

Group type: EXPERIMENTAL
Intervention: Reference formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Test formulation (40 mg pantoprazole enteric coated tablets) under fasting condition
Number of subjects: 98

Group type: COMPARATOR
Intervention: Reference formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Number of subjects: 98

Group type: COMPARATOR
Intervention: Test formulation (40 mg pantoprazole enteric coated tablets) under fed condition
Number of subjects: 98
Study: 16081748

Group type: EXPERIMENTAL
Intervention: Parent self-reported home safety practices (smoke detectors, bike helmets, car seats, water heater temperature)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Car seat types
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported practices (owning a car seat, hot water temperatures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported practices (working smoke detectors, properly fitting bike helmets)
Number of subjects: 0
Study: 12353900

Group type: EXPERIMENTAL
Intervention: PCCC with optic capture of the PC IOL (Group B)
Number of subjects: 34

Group type: COMPARATOR
Intervention: ACCC with PCCC without optic capture of the PC IOL (Group A)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 10075140

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 422
Study: 8602475

Group type: EXPERIMENTAL
Intervention: Jamar dynamometer
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Martin vigorimeter
Number of subjects: 360
Study: 2140346

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (resting quietly)
Number of subjects: 18
Study: 7044913

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Follow-up of healed ulcers
Number of subjects: 50
Study: 30652973

Group type: EXPERIMENTAL
Intervention: Isoquercetin 1000 mg daily for 56 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Isoquercetin 500 mg daily for 56 days
Number of subjects: 57
Study: 28912129

Group type: EXPERIMENTAL
Intervention: Laboratory high-intensity interval training (L-HIIT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Home high-intensity interval training (H-HIIT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Home isometric hand-grip training (H-IHGT)
Number of subjects: 18
Study: 26999644

Group type: EXPERIMENTAL
Intervention: Higher hydrocortisone dose (0.4-0.6 mg/kg body weight)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Lower hydrocortisone dose (0.2-0.3 mg/kg body weight)
Number of subjects: 47
Study: 24219409

Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 21810288

Group type: EXPERIMENTAL
Intervention: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-dose oat beta-glucan (1.5 g beta-glucan; oats low - OL)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Minimal beta-glucan (control)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Higher dose oat beta-glucan (30g beta-glucan; oats high - OH) in responders
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Low-dose oat beta-glucan (1.5 g beta-glucan; oats low - OL) in responders
Number of subjects: 87

Group type: COMPARATOR
Intervention: Minimal beta-glucan (control) in responders
Number of subjects: 87
Study: 19446153

Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Exenatide 2.5 microg and Exenatide 5 microg
Number of subjects: 13
Study: 17581195

Group type: EXPERIMENTAL
Intervention: Inhalation of IL-5 (10 microg via nebulizer)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (via nebulizer)
Number of subjects: 19
Study: 17242322

Group type: EXPERIMENTAL
Intervention: Patient-specific ratings
Number of subjects: 292

Group type: COMPARATOR
Intervention: Conventional guidelines
Number of subjects: 292
Study: 15363825

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCBs)
Number of subjects: 103793

Group type: EXPERIMENTAL
Intervention: Dihydropyridine CCBs
Number of subjects: 103793

Group type: EXPERIMENTAL
Intervention: Non-dihydropyridine CCBs
Number of subjects: 103793

Group type: COMPARATOR
Intervention: Other antihypertensive drugs
Number of subjects: 103793
Study: 10708818

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (mianserin alone)
Number of subjects: 70
Study: 9387298

Group type: EXPERIMENTAL
Intervention: Screening group (serum AFP test and ultrasound every 6 months)
Number of subjects: 17920

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 17920
Study: 1290631

Group type: EXPERIMENTAL
Intervention: Digital rectal examination screening (first round)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Digital rectal examination screening (second round)
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 1494

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1494

Group type: EXPERIMENTAL
Intervention: Cost of screening
Number of subjects: 1494
Study: 6147451

Group type: EXPERIMENTAL
Intervention: Low food intake group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary supplement group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Customarily low food intake
Number of subjects: 0
Study: 30538082

Group type: EXPERIMENTAL
Intervention: Synbiotic pomegranate juice (SPJ)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Synbiotic beverage (SB)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo beverage (Control)
Number of subjects: 92
Study: 29851998

Group type: EXPERIMENTAL
Intervention: Water aerobics (45 min, twice a week for 12 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no physical exercise)
Number of subjects: 23
Study: 27788854

Group type: EXPERIMENTAL
Intervention: Endoepicardial scar homogenization
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard limited-substrate ablation
Number of subjects: 93
Study: 24002626

Group type: EXPERIMENTAL
Intervention: Letter + Personal Call
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Letter + Autodial + Prompt
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Letter + Autodial
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Reminder letter
Number of subjects: 1008
Study: 22516444

Group type: EXPERIMENTAL
Intervention: Coronary 18F‐NaF uptake in patients with coronary atherosclerosis (n = 106)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control subjects (calcium score = 0)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Patients with increased coronary 18F‐NaF activity (n = 40)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Coronary 18F‐FDG uptake
Number of subjects: 119
Study: 20142177

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 40
Study: 17451776

Group type: EXPERIMENTAL
Intervention: Orientation masking in an alignment discrimination task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masking a Vernier stimulus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orientation masking on perceived orientation and alignment of a Vernier stimulus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control of task-dependent effects
Number of subjects: 0
Study: 15003432

Group type: EXPERIMENTAL
Intervention: SSRI treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Sexual partner availability
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Treatment remission
Number of subjects: 68
Study: 12240499

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage on the arm 3 times a week for 4 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 9695995

Group type: EXPERIMENTAL
Intervention: Ribavirin alone (1,000 mg/daily for 6 months) followed by interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ribavirin plus interferon alfa n‐3 for 6 months at the above doses
Number of subjects: 96

Group type: COMPARATOR
Intervention: Interferon alfa n‐3 alone (3 MU thrice weekly for 6 months)
Number of subjects: 96
Study: 7911406

Group type: EXPERIMENTAL
Intervention: Terazosine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Terazosine and Buflomedil combination
Number of subjects: 46
Study: 2734402

Group type: EXPERIMENTAL
Intervention: Nasal packing
Number of subjects: 50

Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 50
Study: 31485457

Group type: EXPERIMENTAL
Intervention: Vildagliptin plus low-dose metformin (VLDM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose metformin (HDM)
Number of subjects: 0
Study: 29096181

Group type: EXPERIMENTAL
Intervention: Online interactive typing intervention (two online games played at home for four weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no online games)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Online interactive typing intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 26735057

Group type: EXPERIMENTAL
Intervention: Closed-suction drains in the subcutaneous tissue
Number of subjects: 42

Group type: COMPARATOR
Intervention: Progressive tension sutures
Number of subjects: 42
Study: 24965545

Group type: EXPERIMENTAL
Intervention: SAGB (single anastomosis gastric bypass)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SG (sleeve gastrectomy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SAGB
Number of subjects: 60

Group type: COMPARATOR
Intervention: SG
Number of subjects: 60
Study: 22156332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single-dose pregabalin (150 mg before surgery)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Multidose pregabalin (150 mg presurgery and at 12 and 24 hours)
Number of subjects: 48